• br Conflicts of interest br Introduction Arginase catalyzes

  2024-12-06

  

  Conflicts of interest Introduction Arginase catalyzes the reaction in which l-arginine is converted to l-ornithine and urea. In humans, two arginase isoenzymes have been identified, arginase 1 and arginase 2, that differ in cellular location and tissue distribution [1]. Both arginase enzymes a

• br Nanoparticle Conjugated Topoisomerase Inhibitors The safe

  2024-12-06

  

  Nanoparticle-Conjugated Topoisomerase Inhibitors The safety and efficacy of topotecan administered as LDM or MTD have been evaluated in several preclinical studies and a few clinical trials whose results showed that there can be significant adverse effects likely precluding its use in patients [5

• We designed SSOs that block APP exon splicing and

  2024-12-06

  

  We designed SSOs that block APP exon 17 splicing and induce the production of an alternatively spliced APP mRNA lacking exon 17 (APPΔex17). APPΔex17 mRNA encodes an APP protein isoform that lacks 49 biotin dctp including the γ-secretase cleavage sites that give rise to the toxic, AD-associated Aβ42

• br Results br Discussion Many tumor cells rely on EAAs

  2024-12-05

  

  Results Discussion Many tumor Adarotene rely on EAAs to provide fundamental building blocks for macromolecular biosynthesis because they cannot synthesize EAAs de novo (Hattori et al., 2017; Sheen et al., 2011). Therefore, they must use highly effective transporters to maximize EAA uptake fro

• br Introduction There are greater than

  2024-12-05

  

  Introduction There are greater than five million Americans living with Alzheimer's dementia and more than 35 million people worldwide [1], and without a way to stop or slow the progression, there will be nearly a tripling of individuals affected by 2050 (13.8 million) [1]. The urgency to develop

• br Conflict of interest br Acknowledgements The

  2024-12-05

  

  Conflict of interest Acknowledgements The authors would like to thank Mrs. Amparo Pacheco from CMPL, PUC, for her technical and secretarial assistance. This work was supported by the Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT 1150344, 1050377, 11150083), and the Direccioń

• Dipraglurant AdipoRon is an orally active synthetic small mo

  2024-12-05

  

  AdipoRon is an orally active, synthetic small molecule that activates adiponectin receptor (AdipoR). It mimics the antidiabetic effects of adiponectin, exhibiting its effect through the activation of AMPK and PPARα pathways via AdipoR1 and AdipoR2, respectively (Fig. 2) [62]. AdipoR activation has r

• br Conflict of interest br

  2024-12-05

  

  Conflict of interest Financial support Acknowledgments This work was supported by the Japanese Millennium project. We thank all members of the Center for Genomic Medicine of RIKEN and Dainippon-Sumitomo Pharma Co., Ltd. for supporting this study. We are also grateful to members of the Hiros

• Both subcutaneous s c and

  2024-12-05

  

  Both subcutaneous (s.c.) and mucosal administration of short synthetic peptide derivatives of AChR prevent the onset of EAMG, but do not treat ongoing EAMG [80], [81], [82], [83], [84], [85]. The selection of peptides for treatment is mainly based on the identification of immunodominant T- and B-cel

• hoechst 33342 The synthetic route to M developed

  2024-12-05

  

  The synthetic route to M100907 developed by Rice was utilized, however, the chiral resolution was carried out at an earlier stage to provide the possibility of introducing different substituents onto the piperidinyl group. The conditions for this resolution were different from previously reported.

• Receptor tyrosine kinase Axl is a member of the

  2024-12-05

  

  Receptor tyrosine kinase Axl is a member of the TAM (Tyro3/Axl/Mer) family, and has reported been associated with a spectrum of human cancers [8]. Numerous studies have revealed that the oncogenic potential of Axl is attributed to the anti-apoptotic and proliferative signaling pathways triggered by

• Docking studies were performed on the selected compounds to

  2024-12-05

  

  Docking studies were performed on the selected compounds to explore their binding patterns and to examine SAR in more detail. The co-crystal structure of ATX in complex with PF-8380 (PDB code: ) was selected for the docking studies due to structural similarity of the most potent compound with PF-83

• br Conclusions br Author declaration br Acknowledgements br

  2024-12-04

  

  Conclusions Author declaration Acknowledgements Introduction ASK1 scaffolding proteins ASK1 adaptor proteins Conclusions Scaffolding and adaptor proteins can coordinate the specific activation of a MAP3K-MAP2K-MAPK pathway in response to various stimuli. For example, both querce

• In our approach using BRET and FRET there is a

  2024-12-04

  

  In our approach using BRET and FRET, there is a substantial increase in BRET and FRET signals between Giα2 or Giα3-YFP and CFP- Gγ2/Rluc-Gγ2 upon apelin-13 activation, indicating that Gαi2, Gαi3 and N-terminus of Gβ1γ2 subunits become closer without subunit dissociation. In contrast, both the FRET a

• It is worth noting that in S

  2024-12-04

  

  It is worth noting that in S. cerevisiae, the control of two cell-cycle checkpoints requiring Mcm1 involves two very different mechanisms. At the G1/S transition, Mcm1 transactivation activity is inhibited by Yox1 and Yhp1 repressors, whose expression is periodically regulated through the cell cycle

8063 records 83/538 page Previous Next First page 上5页 8182838485 下5页 Last page